Fate Therapeutics Names Executive Chairman
Earlier this week we reported that bi-coastal biotech Fate Therapeutics had named its new CEO, Paul Grayson. Today the company officially announced Grayson, as well as the appointment of John Mendlein as executive chairman. Mendlein was most recently CEO of Boston-based Adnexus Therapeutics, which was bought by Bristol-Myers Squibb last October for more than $505 million. Fate Therapeutics is backed chiefly by Polaris Venture Partners in Waltham, MA, and Arch Venture Partners in Seattle, WA.